Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06994351
Starting soon Not applicable

Acupuncture for Anxiety and Depression

NCT06994351 · tracked via the Priya Life Science China tracker
Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase
Not applicable
Started
2025-05-18
Last updated
2025-05-29

Condition(s) studied

Anxiety and DepressionBreast Cancer Survivor

Investigational drug(s) / intervention(s)

ElectroacupunctureSham electroacupuncture

Electroacupuncture: The needles will be inserted to 15-40mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 10-minute maintenance in prone and supine position respectively. The electronic acupuncture apparatus will be connected to the bileteral Taiyang, Anmian and Baihui, with a continuous wave of 2 Hertz (Hz) and an electric current of 1-3 milliampere (mA). Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks.

Sham electroacupuncture: The needle will be inserted to 2-3mm in Bai Hui acupoint. For the remaining acupoints, needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin. The electronic acupuncture apparatus will be connected to the Baihui acupoint, Shang Yin Tang acupoint, and bilateral Anmian acupoints, with a continuous wave of 2 Hertz (Hz) and an electric current of 0.1-0.3 mA. In about 30 seconds, the electric current will be turned down. Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks.

Study summary

The study aims to primarily investigate the effects and safety of acupuncture on anxiety and depression among patients with breast cancer.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion criteria 1. Female, aged 18 to 70 years old; 2. Meeting the diagnostic criteria for breast cancer and at TMN I-III; 3. Having completed specialized active treatment for at least one month; 4. With an ECOG score of 0-2; 5. Mild to moderate anxiety and/or depression; 6. Voluntarily joining this study and signing the informed consent form. Exclusion criteria (1) Starting to take or change the regimen of anti-anxiety and/or -depression disorder medication within one month before enrolment; (2) Received psychological intervention or physical therapy one month before enrolment or planning to use in the next 5 months; (3) With diagnosis of anxiety and/or depression disorder prior to the diagnosis of breast cancer; (4) Patients with suicidal tendencies, bipolar disorder and psychotic symptoms; (5) Patients with severe anxiety and/or depression； (6) Patients received acupuncture treatment within one month before enrolment; (7) Participating in other clinical studies on the treatment of anxiety and depression; (8) Combined with severe underlying diseases; (9) Patients with severe skin ulcers; (10) Pregnant or lactating patients; (11) Poor compliance.

Primary outcome measure(s)

  • The change from baseline in the Hospital Anxiety and Depression Scale (HADS) — week 8
    The HADS score ranges from 0 to 42, with higher scores indicating greater anxiety and depression.

Trial sites (1)

FacilityCityRegionStatus
China Academy of Chinese Medical Sciences Beijing China

More Guang'anmen Hospital of China Academy of Chinese Medical Sciences trials in China

Efficacy and Central Mechanisms of Electroacupuncture for Medication Overuse Headache Recruiting
Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer Recruiting
The Efficacy and Safety of Acupuncture for Prophylaxis of Menstrually Related Migraine Recruiting
GenAI-Assisted Rheumatoid Arthritis Bone Erosion Risk Assessment and DMARD Selection Recruiting
Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer Recruiting

Other trials for the same condition

Baduanjin Exercise on Upper Limb Dysfunction Among Breast Cancer Survivors Starting soon
Transcranial Direct Current Stimulation for Cancer-related Cognitive Impairment in Breast Cancer Survivors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06994351 on ClinicalTrials.gov ↗ ← All trials in China